New Liquidia Logo.png
Liquidia to Participate at H.C. Wainwright 23rd Annual Global Investment Conference
September 10, 2021 08:29 ET | Liquidia Corporation
MORRISVILLE, N.C., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Damian deGoa, Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual...
New Liquidia Logo.png
FDA Completes On-site Pre-Approval Inspection of Liquidia’s Morrisville, North Carolina Facility
August 18, 2021 16:15 ET | Liquidia Corporation
MORRISVILLE, N.C., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) has completed an on-site Pre-Approval...
New Liquidia Logo.png
U.S. Patent Trial and Trademark Appeal Board Decides to Institute Inter Partes Review of United Therapeutics’ Tyvaso® Patent
August 12, 2021 08:00 ET | Liquidia Corporation
MORRISVILLE, N.C., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Patent Trial and Appeal Board (PTAB) has instituted inter partes review (IPR)...
New Liquidia Logo.png
Liquidia Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 10, 2021 07:00 ET | Liquidia Corporation
Launched subcutaneous delivery of Treprostinil Injection, doubling market opportunityResubmitted New Drug Application (NDA) for LIQ861 (treprostinil) inhalation powderImproved balance sheet with...
New Liquidia Logo.png
Liquidia to Report Second Quarter 2021 Financial Results on August 10, 2021
August 03, 2021 07:00 ET | Liquidia Corporation
MORRISVILLE, N.C., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its second quarter 2021 financial results on Tuesday, August 10, 2021....
New Liquidia Logo.png
Liquidia Announces FDA Acceptance of New Drug Application Resubmission for LIQ861 (treprostinil) Inhalation Powder
June 02, 2021 07:00 ET | Liquidia Corporation
MORRISVILLE, N.C., June 02, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA)...
New Liquidia Logo.png
Liquidia Corporation To Present At The Jefferies Virtual Healthcare Conference
May 26, 2021 07:00 ET | Liquidia Corporation
MORRISVILLE, N.C., May 26, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Damian deGoa, Chief Executive Officer of Liquidia, will provide an overview and...
New Liquidia Logo.png
Liquidia Announces Generic Treprostinil Injection Now Also Available for Subcutaneous Route of Administration
May 24, 2021 16:05 ET | Liquidia Corporation
MORRISVILLE, N.C., May 24, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced that Sandoz Treprostinil Injection, a generic form of...
New Liquidia Logo.png
Liquidia Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 13, 2021 07:00 ET | Liquidia Corporation
- Doubled the market opportunity for Treprostinil Injection by adding subcutaneous delivery- Resubmitted New Drug Application for LIQ861 (treprostinil) Inhalation Powder- Improved financial position...
New Liquidia Logo.png
Liquidia Resubmits New Drug Application for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension
May 10, 2021 06:30 ET | Liquidia Corporation
MORRISVILLE, N.C., May 10, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that on May 7, 2021, it resubmitted its New Drug Application (NDA) for LIQ861 for the...